Syndax Pharmaceuticals Presents Data Showing Revuforj Achieved 90% Two-Year Overall Survival Post-Transplant In Acute Leukemia Patients, With Favorable Pharmacokinetic Profile Supporting Flexible Administration At ASCO 2026

Loading news article.

Syndax Pharmaceuticals Presents Data Showing Revuforj Achieved 90% Two-Year Overall Survival Post-Transplant In Acute Leukemia Patients, With Favorable Pharmacokinetic Profile Supporting Flexible Administration At ASCO 2026 | WAPE

Syndax Pharmaceuticals Presents Data Showing Revuforj Achieved 90% Two-Year Overall Survival Post-Transplant In Acute Leukemia Patients, With Favorable Pharmacokinetic Profile Supporting Flexible Administration At ASCO 2026

Article summary

Related companies

Comments —